Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Filings indexed 672 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Annual Secretarial Compliance Report for the year ended March 31, 2026
Regulatory Filings Classification · 85% confidence The document is a Secretarial Compliance Report pursuant to SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, prepared by the company secretary and filed with stock exchanges. It does not present full financial statements or constitute an Annual/Interim Report, nor is it an earnings release, AGM material, or similar. It is a compliance document falling under general regulatory filings. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-20 English
Q4FY26 Earnings Call Transcript
Call Transcript Classification · 92% confidence The document is a letter to stock exchanges enclosing the full text of the Q4 FY'26 earnings conference call transcript, including the moderator’s introduction, speaker line-up, management presentations with financial details, and Q&A format. This matches the definition of a Call Transcript rather than an earnings release or report. Therefore, it should be classified as CT.
2026-05-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 98% confidence The document is the full text transcript of Gland Pharma’s Q4 FY26 earnings conference call, including moderator directions, management presentations, and financial performance discussion, which aligns with the definition of a Call Transcript.
2026-05-20 English
Schedule of Investor Meet
Regulatory Filings Classification · 85% confidence The document is an intimation under SEBI Listing Obligations (Regulation 30) providing the schedule of analyst/institutional investor meetings. It is a compliance/regulatory announcement rather than a substantive financial report (e.g., annual report, earnings release) or management presentation. It does not contain financial statements or management discussion, but is a standard regulatory disclosure to stock exchanges. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-05-18 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2026-05-18 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 85% confidence The document is a formal letter to the stock exchanges enclosing newspaper advertisements of the audited financial results for FY26, in compliance with SEBI Listing Regulations. It does not itself contain the full financial statements or detailed data, but rather announces and provides copies of the ads and points investors to the website for the full results. This fits the definition of a Report Publication Announcement (RPA) rather than an actual annual or interim report.
2026-05-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.